Metformin Prevents Alcohol-Induced Liver Injury in the Mouse: Critical Role of Plasminogen Activator Inhibitor-1

Gastroenterology

Volumn 130, Issue 7, 2006, Pages 2099-2112

  Bergheim, Ina ^a   Guo, Luping ^a   Davis, Molly Anne ^a   Lambert, Jason C ^a   Beier, Juliane I ^a   Duveau, Ilinca ^a   Luyendyk, James P ^b   Roth, Robert A ^b   Arteel, Gavin E ^a  

^a University of Louisville School of Medicine   (United States)

^b National Food Safety and Toxicology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ALCOHOL; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FATTY LIVER; GENE EXPRESSION; HISTOPATHOLOGY; KNOCKOUT MOUSE; LIVER INJURY; LIVER PROTECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; UPREGULATION;

EID: 33744537874     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.03.020     Document Type: Article

References (59)

1. Grant B.F., Dufour M.C., and Harford T.C. Epidemiology of alcoholic liver disease. Semin Liver Dis 8 (1988) 12-25
2. MacSween R.N., and Burt A.D. Histologic spectrum of alcoholic liver disease. Semin Liver Dis 6 (1986) 221-232
3. Day C.P., and James O.F. Hepatic steatosis. innocent bystander or guilty party?. Hepatology 27 (1998) 1463-1466
4. Harrison S.A., and Diehl A.M. Fat and the liver-a molecular overview. Semin Gastrointest Dis 13 (2002) 3-16
5. Arteel G.E. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 124 (2003) 778-790
6. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., Luketic V.A., Shiffman M.L., and Clore J.N. Nonalcoholic steatohepatitis. association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
7. Saglam K., Kilic R., Yilmaz M.I., Gulec M., Baykal Y., and Kutlu M. Insulin resistance in patients with steatohepatitis. Hepatogastroenterology 50 (2003) 456-459
8. Nair S., Diehl A.M., Wiseman M., Farr Jr. G.H., and Perrillo R.P. Metformin in the treatment of non-alcoholic steatohepatitis. a pilot open label trial. Aliment Pharmacol Ther 20 (2004) 23-28
9. Lin H.Z., Yang S.Q., Chuckaree C., Kuhajda F., Ronnet G., and Diehl A.M. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6 (2000) 998-1003
10. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., and Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 358 (2001) 893-894
11. Diehl A.M., Goodman Z., and Ishak K.G. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 95 (1988) 1056-1062
12. Hall P.D. Pathological spectrum of alcoholic liver disease. Alcohol Alcohol Suppl 2 (1994) 303-313
13. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., and Moller D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 (2001) 1167-1174
14. Yin M., Wheeler M.D., Kono H., Bradford B.U., Gallucci R.M., Luster M.I., and Thurman R.G. Essential role of tumor necrosis factor α in alcohol-induced liver injury. Gastroenterology 117 (1999) 942-952
15. Yazar A., Polat G., Un I., Levent A., Kaygusuz A., Buyukafsar K., and Camdeviren H. Effects of glibenclamide, metformin and insulin on the incidence and latency of death by oubain-induced arrhythmias in mice. Pharmacol Res 45 (2002) 183-187
16. Enomoto N., Ikejima K., Yamashina S., Enomoto A., Nishiura T., Nishimura T., Brenner D.A., Schemmer P., Bradford B.U., Rivera C.A., Zhong Z., and Thurman R.G. Kupffer cell-derived prostaglandin E(2) is involved in alcohol-induced fat accumulation in rat liver. Am J Physiol Gastrointest Liver Physiol 279 (2000) G100-G106
17. McKim S.E., Gabele E., Isayama F., Lambert J.C., Tucker L.M., Wheeler M.D., Connor H.D., Mason R.P., Doll M.A., Hein D.W., and Arteel G.E. Inducible nitric oxide synthase is required in alcohol-induced liver injury. studies with knockout mice. Gastroenterology 125 (2003) 1834-1844
18. Thompson J.A., and Reitz R.C. Effects of ethanol ingestion and dietary fat levels on mitochondrial lipids in male and female rats. Lipid 13 (1978) 540-550
19. Morimoto M., Zern M.A., Hagbjork A.L., Ingelman-Sundberg M., and French S.W. Fish oil, alcohol, and liver pathology. role of cytochrome P4502E1. Proc Soc Exp Biol Med 207 (1994) 197-205
20. Anfosso F., Chomiki N., Alessi M.C., Vague P., and Juhan-Vague I. Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. J Clin Invest 91 (1993) 2185-2193
21. van Goor H., Gerrits P.O., and Grond J. The application of lipid-soluble stains in plastic-embedded sections. Histochemistry 85 (1986) 251-253
22. Arteel G.E., Iimuro Y., Yin M., Raleigh J.A., and Thurman R.G. Chronic enteral ethanol treatment causes hypoxia in rat liver tissue in vivo. Hepatology 25 (1997) 920-926
23. Nanji A.A., Mendenhall C.L., and French S.W. Beef fat prevents alcoholic liver disease in the rat. Alcohol Clin Exp Res 13 (1989) 15-19
24. McKim S.E., Konno A., Gabele E., Uesugi T., Froh M., Sies H., Thurman R.G., and Arteel G.E. Cocoa extract protects against early alcohol-induced liver injury in the rat. Arch Biochem Biophys 406 (2002) 40-46
25. You M., and Crabb D.W. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol 287 (2004) G1-G6
26. You M., Matsumoto M., Pacold C.M., Cho W.K., and Crabb D.W. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 127 (2004) 1798-1808
27. Grant P.J., Stickland M.H., Booth N.A., and Prentice C.R. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 8 (1991) 361-365
28. Tomita K., Azuma T., Kitamura N., Nishida J., Tamiya G., Oka A., Inokuchi S., Nishimura T., Suematsu M., and Ishii H. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology 126 (2004) 873-885
29. Tahara M., Matsumoto K., Nukiwa T., and Nakamura T. Hepatocyte growth factor leads to recovery from alcohol-induced fatty liver in rats. J Clin Invest 103 (1999) 313-320
30. Kono H., Rusyn I., Yin M., Gabele E., Yamashina S., Dikalova A., Kadiiska M.B., Connor H.D., Mason R.P., Segal B.H., Bradford B.U., Holland S.M., and Thurman R.G. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 106 (2000) 867-872
31. Li J., Nguyen V., French B.A., Parlow A.F., Su G.L., Fu P., Yuan Q.X., and French S.W. Mechanism of the alcohol cyclic pattern. role of the hypothalamic-pituitary-thyroid axis. Am J Physiol Gastrointest Liver Physiol 279 (2000) G118-G125
32. Teli M.R., Day C.P., Burt A.D., Bennett M.K., and James O.F. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 346 (1995) 987-990
33. Wanless I.R., and Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases. a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 24 (2004) 99-106
34. Thurman R.G., Bradford B.U., Iimuro Y., Knecht K.T., Arteel G.E., Yin M., Connor H.D., Wall C., Raleigh J.A., Frankenberg M.V., Adachi Y., Forman D.T., Brenner D., Kadiiska M., and Mason R.P. The role of gut-derived bacterial toxins and free radicals in alcohol-induced liver injury. J Gastroenterol Hepatol 13 Suppl (1998) S39-S50
35. Adachi Y., Bradford B.U., Gao W., Bojes H.K., and Thurman R.G. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 20 (1994) 453-460
36. Adachi Y., Moore L.E., Bradford B.U., Gao W., and Thurman R.G. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 108 (1995) 218-224
37. Iimuro Y., Ikejima K., Rose M.L., Bradford B.U., and Thurman R.G. Nimodipine, a dihydropyridine-type calcium channel blocker, prevents alcoholic hepatitis due to chronic intragastric ethanol exposure in the rat. Hepatology 24 (1996) 391-397
38. Sawdey M.S., and Loskutoff D.J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 88 (1991) 1346-1353
39. Fearns C., and Loskutoff D.J. Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha. Am J Pathol 150 (1997) 579-590
40. Seki T., and Gelehrter T.D. Interleukin-1 induction of type-1 plasminogen activator inhibitor (PAI-1) gene expression in the mouse hepatocyte line, AML 12. J Cell Physiol 168 (1996) 648-656
41. Kruithof E.K. Plasminogen activator inhibitors-a review. Enzyme 40 (1988) 113-121
42. Ma L.J., Mao S.L., Taylor K.L., Kanjanabuch T., Guan Y., Zhang Y., Brown N.J., Swift L.L., McGuinness O.P., Wasserman D.H., Vaughan D.E., and Fogo A.B. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53 (2004) 336-346
43. Alessi M.C., Bastelica D., Mavri A., Morange P., Berthet B., Grino M., and Juhan-Vague I. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 23 (2003) 1262-1268
44. Venkatesan S., Ward R.J., and Peters T.J. Effect of chronic ethanol feeding on the hepatic secretion of very-low-density lipoproteins. Biochim Biophys Acta 960 (1988) 61-66
45. Guzman M., and Castro J. Zonal heterogeneity of the effects of chronic ethanol feeding on hepatic fatty acid metabolism. Hepatology 12 (1990) 1098-1105
46. Naldini L., Vigna E., Bardelli A., Follenzi A., Galimi F., and Comoglio P.M. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 270 (1995) 603-611
47. Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M., Kmiecik T.E., Vande Woude G.F., and Aaronson S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251 (1991) 802-804
48. Kaibori M., Kwon A.H., Oda M., Kamiyama Y., Kitamura N., and Okumura T. Hepatocyte growth factor stimulates synthesis of lipids and secretion of lipoproteins in rat hepatocytes. Hepatology 27 (1998) 1354-1361
49. Sugimoto T., Yamashita S., Ishigami M., Sakai N., Hirano K., Tahara M., Matsumoto K., Nakamura T., and Matsuzawa Y. Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. J Hepatol 36 (2002) 157-162
50. Kitching A.R., Kong Y.Z., Huang X.R., Davenport P., Edgtton K.L., Carmeliet P., Holdsworth S.R., and Tipping P.G. Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 14 (2003) 1487-1495
51. Holdsworth S.R., Thomson N.M., Glasgow E.F., and Atkins R.C. The effect of defibrination on macrophage participation in rabbit nephrotoxic nephritis. studies using glomerular culture and electronmicroscopy. Clin Exp Immunol 37 (1979) 38-43
52. Loike J.D., el Khoury J., Cao L., Richards C.P., Rascoff H., Mandeville J.T., Maxfield F.R., and Silverstein S.C. Fibrin regulates neutrophil migration in response to interleukin 8, leukotriene B4, tumor necrosis factor, and formyl-methionyl-leucyl-phenylalanine. J Exp Med 181 (1995) 1763-1772
53. Sato Y., Tsuboi R., Lyons R., Moses H., and Rifkin D.B. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells. a self-regulating system. J Cell Biol 111 (1990) 757-763
54. Espevik T., Figari I.S., Shalaby M.R., Lackides G.A., Lewis G.D., Shepard H.M., and Palladino Jr. M.A. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med 166 (1987) 571-576
55. Marshall L.J., Ramdin L.S., Brooks T., DPhil P.C., and Shute J.K. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 171 (2003) 2057-2065
56. Schaffalitzky de Muckadell O.B., Mortensen H., and Lyngsoe J. Metabolic effects of glucocorticoid and ethanol administration in phenformin- and metformin-treated obese diabetics. Acta Med Scand 206 (1979) 269-273
57. Dubas T.C., and Johnson W.J. Metformin-induced lactic acidosis. potentiation by ethanol. Res Commun Chem Pathol Pharmacol 33 (1981) 21-31
58. Bergheim I., Luyendyk J.P., Steele C., Russell G.K., Guo L., Roth R.A., and Arteel G.E. Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J Pharmacol Exp Ther 316 (2006) 1053-1061
59. Bergheim I., Guo L., Davis M.A., Duveau I., and Arteel G.E. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 316 (2006) 592-600